CILNIDIPINE

Details

Stereochemistry	RACEMIC
Molecular Formula	C27H28N2O7
Molecular Weight	492.5204
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COCCOC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)OC\C=C\C3=CC=CC=C3

InChI

InChIKey=KJEBULYHNRNJTE-DHZHZOJOSA-N

InChI=1S/C27H28N2O7/c1-18-23(26(30)35-14-8-11-20-9-5-4-6-10-20)25(21-12-7-13-22(17-21)29(32)33)24(19(2)28-18)27(31)36-16-15-34-3/h4-13,17,25,28H,14-16H2,1-3H3/b11-8+

HIDE SMILES / InChI

Molecular Formula	C27H28N2O7
Molecular Weight	492.5204
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	1
Optical Activity	( + / - )

Description
Sources: http://adis.springer.com/drugs/800001274
Curator's Comment: Description was created based on several sources, including http://www.nevapress.com/cdr/full/17/4/341.pdf | https://www.ncbi.nlm.nih.gov/pubmed/19426250

Cilnidipine (FRC-8653) is a dihydropyridine (DHP) type of calcium channel antagonist. The L-type Ca2+ channel blockade by cilnidipine affects predominantly vascular smooth muscle, thereby producing vasodilation of peripheral resistance vessels and coronary arteries. The blockade of N-type Ca2+ channels affects predominantly peripheral nerve endings of sympathetic neurons, thereby dilating blood vessels by lowering plasma catecholamine levels. Furthermore, renoprotective and neuroprotective effects as well as cardioprotective action of cilnidipine have been demonstrated in clinical practice or animal examinations. Cilnidipine was originated by Fuji & Rebio Pharmaceutical Co., Ltd. and developed jointly with Ajinomoto for the treatment of hypertension. Cilnidipine has been launched in Japan.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Voltage-gated L-type calcium channel 92 Target ID: CHEMBL2095177 Sources: http://www.nevapress.com/cdr/full/17/4/341.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/10784100 \| https://www.ncbi.nlm.nih.gov/pubmed/10408255	Inhibitor 8297		4.77 null [pIC50]
Voltage-gated N-type calcium channel alpha-1B subunit 12 Target ID: CHEMBL5107 Sources: http://www.nevapress.com/cdr/full/17/4/341.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/10784100 \| https://www.ncbi.nlm.nih.gov/pubmed/10408255	Inhibitor 8297		6.08 null [pIC50]

Conditions

Condition	Modality	Highest Phase	Product
Hypertension 567 Sources: http://adis.springer.com/drugs/800001274 https://www.ncbi.nlm.nih.gov/pubmed/24407539 https://www.ncbi.nlm.nih.gov/pubmed/27734656	Primary	Approved 8429	ATELEC Approved Use Hypertension
Stroke 144 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15340224	Primary	Preclinical	Unknown Approved Use Unknown
Pain 614 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10841896	Primary	Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Comparison of 24-hour blood pressure, heart rate, and autonomic nerve activity in hypertensive patients treated with cilnidipine or nifedipine retard.	1998 Aug	9700998

Patents

Sample Use Guides

In Vivo Use Guide

Normally once daily 5 to 10 mg of cilnidipine after breakfast orally for adult patient. The dose can be increased or reduced according to the age and symptoms. If the above dose is not effective enough, the dose can be increased to 20 mg once daily. For severe hypertension, 10 to 20 mg of cilnidipine orally once daily after breakfast.

Route of Administration: Oral

In Vitro Use Guide

Cell viability of PC12 was not affected by low concentrations of cilnidipine up to 150 uM, but it was slightly decreased at 200 uM cilnidipine.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:31:16 UTC 2023` Edited by `admin` on `Fri Dec 15 16:31:16 UTC 2023`
Record UNII	97T5AZ1JIP
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CILNIDIPINE

Official Name

English

CILNIDIPINE [JAN]

Common Name

English

cilnidipine [INN]

Common Name

English

SISCARD

Brand Name

English

FRC-8653

Code

English

Cilnidipine [WHO-DD]

Common Name

English

CILNIDIPINE [MART.]

Common Name

English

ATELEC

Brand Name

English

(±)-(E)-CINNAMYL 2-METHOXYETHYL 1,4-DIHYDRO-2,6-DIMETHYL-4-(M-NITROPHENYL)-3,5-PYRIDINEDICARBOXYLATE

Systematic Name

English

CINALONG

Brand Name

English

CILNIDIPINE [MI]

Common Name

English

3,5-PYRIDINEDICARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-4-(3-NITROPHENYL)-, 3-(2-METHOXYETHYL) 5-((2E)-3-PHENYL-2-PROPEN-1-YL) ESTER

Systematic Name

English

Classification Tree Code System Code

WHO-VATC

QC08CA14